Isosorbide dinitrate inhaler and quality of life in stable angina patients
Abstract
Aim. To study quality of life (QoL) dynamics in out-patient individuals with stable angina pectoris, receiving standard basal therapy plus isosorbide dinitrate (ID) in aerosol form: Isoket® aerosol.
Material and methods. In total, 547 patients with effort angina were examined: 351 males (64.2%) and 196 females (35.8%); mean age – 61.2±9.9 years; mean disease duration – 8.9±1.9 years. A questionnaire, previously used in an international study of QoL in stable angina patients treated with nitrates, IQOLAN, was used. Standard basal therapy in most participants included beta-adrenoblockers and heart rate-reducing calcium antagonists. For treatment and prevention of anginal episodes, Isoket® aerosol was administered (12.7 g of ID in 15.0 ml), instead of nitroglycerin and nitrosorbide; the effect was assessed after three months of therapy.
Results. Therapy with ID aerosol was associated with substantial improvement in physical stress tolerance. QoL dynamics differed in patients with various angina functional classes (FC). Severity of anginal symptoms reduced, as well as their frequency: in females - from 79.8% to 41.4%; in males – from 80.7% to 41.1%. In subgroup with IV FC, the percentage of “substantial QoL deterioration” decreased: in females - from 100% to 60%, in males – from 94.6% to 47.8%.
Conclusion. ID aerosol was highly effective for treating angina episodes in virtually all patients. Its preventive administration improved QoL, especially in patents with angina-related restriction of physical activity.
About the Authors
A. A. Kirichenko
Russian Medical Academy of Continuous Medical Education, Moscow
Russian Federation
Russian Federation
L. N. Panchuk
Russian Medical Academy of Continuous Medical Education, Moscow
Russian Federation
Russian Federation
References
1. Vogt D, Trenk D, Bonn R, Jahnchen E. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. Eur J Clin Pharmacol 1994; 46(4): 319-24.
2. Hutt V, Theodor R, Pabst G, et al. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. Arzneimittel forschung 1993; 43(8): 842-6.
3. Marchionni N, De Bari M, Ferrucci L, et al. Comparative study of time-course hemodynamic effect of isosorbide dinitrate spray and sublingual tablets in patietns with pulmonary congestion. Cardiovasc Drugs Ther 1988; 2(4): 529-32.
4. Marmor A. Comparative evaluation of a new formulation of isosorbide dinitrate oral spray and sublingual nitroglycerin tablets. Am J Cardiol 1990; 65: 43J-5.
5. Reisin LH, Landau E, Darawshi A, et al. More rapid relief of pain with isosorbide dinitrate spray than with sublingual tablets in elderly patients with angina pectoris. Am J Cardiol 1988; 61(9): 2E-3.
6. Ольбинская Л.И., Сизова Ж.М., Ушакова А.В. Сравнительная эффективность, безопасность, кардиогемодинамические эффекты аэрозоля изосорбида динитрата и сублингвальных таблеток нитроглицерина. Тер архив 1998; 5: 69-72.
7. Беленков Ю.Н., Чазова И.Е., Ратова Л.Г. и др. Результаты международного исследования качества жизни пациентов со стабильной стенокардией на фоне терапии нитратами (IQOLAN). Кардиология 2003; 9: 4-7.
Review
For citations:
Kirichenko A.A., Panchuk L.N. Isosorbide dinitrate inhaler and quality of life in stable angina patients. Cardiovascular Therapy and Prevention. 2005;4(3, ч.I):72-76. (In Russ.)
Views:
553
Email this article 
